Detecting markers for gastric cancer and developing a diagnostic kit
Official title: Gastric Cancer Marker Detection and Its Kit Development
Run by Second Affiliated Hospital of Wenzhou Medical University · NCT05010863 · Data updated 2026-11-12
This study is testing a new way to find signs of gastric cancer in blood samples to help doctors diagnose it more accurately and earlier.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 530 (estimated) |
| Sponsor | Second Affiliated Hospital of Wenzhou Medical University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Wenzhou, Zhejiang) |
| Status | Recruiting |
| Started | January 1, 2021 |
| Main results expected | December 30, 2023 |
| Study ends | December 30, 2030 |
| Registry record updated | August 18, 2021 |
| Trial ID | NCT05010863 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older diagnosed with early or advanced gastric cancer who have not received prior anti-tumor treatments.
✕Probably not a fit
Patients with a history of other tumors, autoimmune diseases, or those who have undergone previous anti-tumor treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to identify new tumor markers for gastric cancer using protein chips, which will enhance the sensitivity and specificity of diagnosis. It involves recruiting patients with early and advanced gastric cancer, as well as healthy controls, to collect blood samples for analysis. The study will establish a multi-diagnostic model for early screening and produce monoclonal antibodies against identified markers to create a diagnostic kit. The goal is to improve the efficiency and accuracy of gastric cancer detection.
Why it matters
Potential benefit: If successful, this could lead to earlier and more accurate diagnosis of gastric cancer, improving patient outcomes.
How similar studies have gone: While there have been studies focusing on gastric cancer markers, this approach utilizing protein chips for multi-diagnostic models is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: patient 1. Age is greater than or equal to 18 years old (including 18 years old); 2. Patients who are diagnosed with cancer after pathological diagnosis; 3. Can provide enough tissue samples; 4. Have not received anti-tumor treatment in the past; 5. Comply with the principle of informed consent and sign the informed consent form. healthy person: 1. Age is greater than or equal to 18 years old (including 18 years old); 2. No underlying disease; 3. Can provide enough tissue samples; 4. Comply with the principle of informed consent and sign the informed consent form. Exclusion Criteria: 1. The tumor foci cannot be clearly derived from a specific tumor type; 2. Those who have a history of other tumors, autoimmune diseases and allergies; 3. Previously received anti-tumor treatments such as surgery, chemotherapy, radiotherapy, molecular targeted therapy, immunotherapy, biological therapy or Chinese medicines with anti-cancer and anti-tumor effects in the instructions; 4. Participated in any clinical trial within 90 days before the experiment; 5. Received major surgery within 90 days before the experiment; 6. Received bone marrow transplantation 90 days before the experiment; 7. Subjects who may not be able to complete the study due to other reasons or who are determined by the investigator to be unsuitable to participate in this study.
Where it's running
-
No. 109, Xueyuan West Road, Lucheng District, Wenzhou City，Zhejiang provincece
Wenzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Weijian Sun, PhD
- Email: fame198288@126.com
- Phone: 13857772361
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.